Loading stock data…
Johnson & Johnson (JNJ)
$275.23-3.20 (-1.15%)
Market ClosedLast close Sep 4
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Johnson & Johnson in the Healthcare sector is trading at $275.23 with a market capitalization of $644.3B. Wall Street consensus targets $275.64 (22 analysts), implying a +0.1% move over the next 12 months. The stock is currently near its 52-week high of $281.07, remaining 17.9% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $25.31B↑ | $24.06B↓ | $24.56B↑ | $23.99B↑ | $23.74B |
| Gross Profit | $17.26B↑ | $15.96B↓ | $16.60B↓ | $16.69B↑ | $16.11B |
| Operating Income | $7.17B↑ | $6.39B↑ | $5.59B↓ | $7.10B↑ | $6.71B |
| Net Income | $5.53B↑ | $5.24B↑ | $5.12B↓ | $5.15B↓ | $5.54B |
Peer Comparison
UNHPFEABBV
Fundamentals
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative M...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$644.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.75
Beta
Defensive asset. Lower volatility than the S&P 500.
0.23
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.90%
ROE
Elite ROE. Management converts capital into profit efficiently.
24.76%
Volume
Today's trading volume
3.88M
Recent News
Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?
Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.
Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?
Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.
3 Dividend Kings Built to Keep Raising Your Income When Rates Rise
Treasury yields near a one-year high are punishing most dividend stocks, but a handful of Dividend Kings kept signing bigger checks every single quarter without missing a beat. The question is whether their balance sheets can keep that streak alive.
How Much Upside Can BSX Stock's Growth Deliver?
While two high-profile segments - WATCHMAN and Electrophysiology - have stumbled, the market is overlooking the company's core stability. Business units representing roughly 75% of revenue are performing consistently with their historical track record, though this durable base's near-term ~6% growth leaves our 10.8% three-year CAGR reliant on a post-2026 pipeline re-acceleration.
Was JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.